Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00186290
Status:
COMPLETED
Last Update Posted:
2010-10-11
First Post:
2005-09-13
Brief Title:
Allo BMT in Advanced Leukemia or High Grade Lymphoma
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Fractionated Total Body Irradiation FTBI Etoposide VP-16 and Cyclophosphamide CY Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma
Detailed Description:
To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure in relapse or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors Fractionated Total Body Irradiation FTBI Etoposide VP-16 and Cyclophosphamide CY Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCT00186290 | None | None | None |
| 74165 | None | None | None |
| BMT34 | None | None | None |